Subscribe To

Price Alert Latest News Economic Calendar News

DBTX / Regeneron buying small cap Decibel Therapeutics for $4 a share

Regeneron Pharmaceuticals Inc. REGN, +0.72% said Wednesday it would pay $4 a share for Decibel Therapeutics Inc. DBTX, +1.09%, a 43% premium over its closing price of $2.79 a share in the previous session. Boston-based Decibel Therapeutics is a clinical-stage biotechnology company with a focus on discovering and developing transformative treatments to restore and improve hearing and balance. Read More

Demo Live Account See Partner Details

Content Topics

Regeneron

Buying

Small

Decibel

Therapeutics

Stock

DBTX

Posted: Aug 9 2023, 07:55

Author Name: Market Watch

DBTX News

By Seeking Alpha
September 15, 2023

Decibel Therapeutics' CVR Appears Around Fair Value

Decibel Therapeutics is being acquired by Regeneron for a cash consideration of $4/share and a CVR linked to DB-OTO. DB-OTO is a gene therapy for hear

By Investopedia
August 9, 2023

Decibel Therapeutics Shares Soar on Acquisition by Regeneron Pharmaceuticals

Shares of Decibel Therapeutics skyrocketed after Regeneron Pharmaceuticals agreed to buy the biotech firm for up to $213 million to expand its gene th

By InvestorPlace
August 9, 2023

Decibel Therapeutics (DBTX) Stock Skyrockets 71% on Regeneron Deal

Decibel Therapeutics (NASDAQ: DBTX ) stock is soaring higher on Wednesday after signing a deal with Regeneron Pharmaceuticals (NASDAQ: REGN ). This de

By Proactive Investors
August 9, 2023

Decibel Therapeutics shoots up 72% on Regeneron bid

Shares of Boston's Decibel Therapeutics Inc soared 72% in the first minutes of trading after Regeneron Pharmaceuticals weighed looks calculated to be

By Market Watch
August 9, 2023

Regeneron buying small cap Decibel Therapeutics for $4 a share

Regeneron Pharmaceuticals Inc. REGN, +0.72% said Wednesday it would pay $4 a share for Decibel Therapeutics Inc. DBTX, +1.09%, a 43% premium over its

By Benzinga
June 28, 2022

Decibel Therapeutics Delivers Solid Interim Data From Cisplatin-Associated Hearing Loss Study

Decibel Therapeutics Inc (NASDAQ: DBTX) reported positive top-line results from an interim analysis of its ongoing Phase 1b clinical trial of DB-02

By GlobeNewsWire
March 22, 2022

Decibel Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and de

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.